Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28318059.
- Also identified by DOI 10.1002/ana.24921.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid β1-42 (≥640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment: HR = 0.19, p < .01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid β1-42 levels within the normal range into account. Ann Neurol 2017;81:749-753.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Cognitive Dysfunction
- Disease Progression
- Memory Disorders
- Peptide Fragments